Przejdź do zawartości
Merck

Single-cell transcriptomic analysis reveals disparate effector differentiation pathways in human Treg compartment.

Nature communications (2021-06-25)
Yuechen Luo, Changlu Xu, Bing Wang, Qing Niu, Xiuhua Su, Yingnan Bai, Shuxian Zhu, Chunxiao Zhao, Yunyan Sun, Jiali Wang, Maolan Liu, Xiaolei Sun, Ge Song, Haidong Cui, Xiaoli Chen, Huifang Huang, Haikun Wang, Mingzhe Han, Erlie Jiang, Lihong Shi, Xiaoming Feng
ABSTRAKT

Human FOXP3+ regulatory T (Treg) cells are central to immune tolerance. However, their heterogeneity and differentiation remain incompletely understood. Here we use single-cell RNA and T cell receptor sequencing to resolve Treg cells from healthy individuals and patients with or without acute graft-versus-host disease (aGVHD) who undergo stem cell transplantation. These analyses, combined with functional assays, separate Treg cells into naïve, activated, and effector stages, and resolve the HLA-DRhi, LIMS1hi, highly suppressive FOXP3hi, and highly proliferative MKI67hi effector subsets. Trajectory analysis assembles Treg subsets into two differentiation paths (I/II) with distinctive phenotypic and functional programs, ending with the FOXP3hi and MKI67hi subsets, respectively. Transcription factors FOXP3 and SUB1 contribute to some Path I and Path II phenotypes, respectively. These FOXP3hi and MKI67hi subsets and two differentiation pathways are conserved in transplanted patients, despite having functional and migratory impairments under aGVHD. These findings expand the understanding of Treg cell heterogeneity and differentiation and provide a single-cell atlas for the dissection of Treg complexity in health and disease.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Anti-SUB1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution